CA
NZ
UK
AU
IND
US
AstraZeneca (OTC: AZNCF) posted earnings per share of $2.63 for the quarter, exceeding the consensus estimate of $2.55. Core earnings grew 18% year‑over‑year, and revenue remained in line with expectations for the year, prompting a positive response in market valuation. This performance showcases the …
Co-Diagnostics, Inc. (NASDAQ: CODX) has revised its equity distribution agreement with Maxim Group LLC, eliminating the previously set aggregate offering price limitation. The amendment lifts the earlier constraint that capped the total offering at $10 million, thereby granting the company expanded latitude to raise …
Citigroup Global Markets Holdings Inc. has priced a new series of medium-term senior notes offering contingent coupon payments linked to the performance of Take-Two Interactive Software, Inc. stock. The securities, issued on July 24, 2026, mature on August 27, 2027, and feature an annualized …
The voucher originated from a prior regulatory milestone when the FDA granted a priority review entitlement following approval of a therapy for a genetic disorder. This cash infusion arrives at a time when the company seeks to extend its runway for pipeline advancement and …
Freenome announced that its SimpleScreen™ CRC test has earned FDA clearance. This blood‑based assay is intended for adults at average risk of colorectal cancer, offering an alternative to traditional stool‑based methods. With an estimated 60 million people in the United States who have not …
Executives at USANA Health Sciences exercised stock options, indicating potential shifts in company strategy. This activity could signal confidence in the firm's future performance, which may influence investor sentiment.Key HighlightsExecutives at USANA Health Sciences exercised stock options on July 27.This action might suggest a …
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has announced a significant leadership change with the appointment of Terence Rooney as the new Chief Medical Officer (CMO). This transition comes as Jared Gollob, MD, prepares to retire after more than eight years of steering the company’s clinical …
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has disclosed its financial results for the second quarter of 2026, marking a noteworthy $0.2 million in revenue. This figure represents the company's first revenue recognition, primarily driven by grant funding related to its proteoform assay development and sales …
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, has secured a important reprieve for its continued listing on the NYSE American. The exchange accepted Picard Medical’s compliance plan, granting the company a pathway to rectify its financial and operational …
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) recorded a loss per share of $-0.05 for the quarter ended March 31, missing the consensus estimate of $-0.04. The company’s shares have risen markedly year‑to‑date, reflecting investor optimism despite the earnings shortfall. This performance comes as …
Please wait processing your request...